Jmcil and Bobbythebus,
With regard to the USA Today article, there have been some interesting posts about that article on Yahoo. I will copy and paste several below. (I am not sure if it is acceptable to copy from other boards - I assume mods will delete this post if this is not appropriate). It appears she will write about Leronlimab after S-C trial results are announced.
Ross wrote this to the author (Karen Weintraub):
Hello Ms. Weintraub
I read your article in the USA Today and am surprised at the lack of mention of Cytodyn's leronlimab, a monoclonal antibody whose phase 3 clinical trial for severe/critical COVID patients completed enrollment a few weeks ago. Unlike the other therapeutics you mentioned, leronlimab completed enrollment without the midterm recommendations to change endpoints or increase sample size to help achieve statistical significance. Their results are waiting to be unblinded around Jan 12, 2021.
Other facts about leronlimab:
- Has been administered to 70+ COVID patients on an eIND basis (more than any other therapeutic) with more to come as FDA has granted Cytodyn the opportunity to fulfill more eIND requests now that their Phase 3 trial is fully enrolled.
- Is injected subcutaneously to the abdomen rather than intravenously (much easier and faster to administer than any aforementioned therapeutic)
- Has been administered to 1,000+ patients in clinical trials with ZERO adverse events (safer than any aforementioned therapeutic)
- Received $0 from OWS or binding Federal funding sources meaning that if proven effective, it will be considered a free agent and available to the first country that will buy the company's current supply
I implore you to investigate for yourself the information available about this product including former Stanford University Director of Virology, Bruce Patterson's research of leronlimab which shows viral load in COVID patients injected with leronlimab drops to ZERO in days while calming the cytokine storm AND normalizing the immune system.
It really is an interesting story.
Thanks for your time. Happy New Year.
Regards
Ross
A few other posters also had some interesting tidbits:
I emailed her when I first read the article. Her response in regards to Leronlimab was, “ Yup. I’ve been following. Thx.”
Thx Ross. I've been having a dialogue with her over the last week, and she directed me to Amy Pyle, who leads USA Today's investigative team. Her earlier responses to me indicated that she would not mention any therapy that either a) had not reported P3 results or b) had been funded by OWS. Given that is the case, I would expect to see an article on leronlimab from her sometime in January, and am laying out for Ms. Pyle what I see as the Big Pharma bias in the actions of our gov't health institutions, at the expense of American lives.
Staying respectful, but not equivocating on what I see as genocidal behavior and BP favoritism on the part of FDA/NIH/BARDA/OWS. They have the megaphone and need to speak out.
I pinged her after she wrote this article the other day (21st, this one must have been updated), as did another poster here. She said she knew about CYDY but was awaiting readout from S/C trial.
@ Ross....I communicated w Karen awhile back introducing her to CYDY.....
FYI...she’s been on some of the Conference Calls. She def knows about Leronlimab!!!!
With regard to the USA Today article, there have been some interesting posts about that article on Yahoo. I will copy and paste several below. (I am not sure if it is acceptable to copy from other boards - I assume mods will delete this post if this is not appropriate). It appears she will write about Leronlimab after S-C trial results are announced.
Ross wrote this to the author (Karen Weintraub):
Hello Ms. Weintraub
I read your article in the USA Today and am surprised at the lack of mention of Cytodyn's leronlimab, a monoclonal antibody whose phase 3 clinical trial for severe/critical COVID patients completed enrollment a few weeks ago. Unlike the other therapeutics you mentioned, leronlimab completed enrollment without the midterm recommendations to change endpoints or increase sample size to help achieve statistical significance. Their results are waiting to be unblinded around Jan 12, 2021.
Other facts about leronlimab:
- Has been administered to 70+ COVID patients on an eIND basis (more than any other therapeutic) with more to come as FDA has granted Cytodyn the opportunity to fulfill more eIND requests now that their Phase 3 trial is fully enrolled.
- Is injected subcutaneously to the abdomen rather than intravenously (much easier and faster to administer than any aforementioned therapeutic)
- Has been administered to 1,000+ patients in clinical trials with ZERO adverse events (safer than any aforementioned therapeutic)
- Received $0 from OWS or binding Federal funding sources meaning that if proven effective, it will be considered a free agent and available to the first country that will buy the company's current supply
I implore you to investigate for yourself the information available about this product including former Stanford University Director of Virology, Bruce Patterson's research of leronlimab which shows viral load in COVID patients injected with leronlimab drops to ZERO in days while calming the cytokine storm AND normalizing the immune system.
It really is an interesting story.
Thanks for your time. Happy New Year.
Regards
Ross
A few other posters also had some interesting tidbits:
I emailed her when I first read the article. Her response in regards to Leronlimab was, “ Yup. I’ve been following. Thx.”
Thx Ross. I've been having a dialogue with her over the last week, and she directed me to Amy Pyle, who leads USA Today's investigative team. Her earlier responses to me indicated that she would not mention any therapy that either a) had not reported P3 results or b) had been funded by OWS. Given that is the case, I would expect to see an article on leronlimab from her sometime in January, and am laying out for Ms. Pyle what I see as the Big Pharma bias in the actions of our gov't health institutions, at the expense of American lives.
Staying respectful, but not equivocating on what I see as genocidal behavior and BP favoritism on the part of FDA/NIH/BARDA/OWS. They have the megaphone and need to speak out.
I pinged her after she wrote this article the other day (21st, this one must have been updated), as did another poster here. She said she knew about CYDY but was awaiting readout from S/C trial.
@ Ross....I communicated w Karen awhile back introducing her to CYDY.....
FYI...she’s been on some of the Conference Calls. She def knows about Leronlimab!!!!
6
